Search
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Milvexian
go.drugbank.com/drugs/DB16233InvestigationalMilvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).
EDI-200
go.drugbank.com/drugs/DB18188InvestigationalEDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
inBreath airway transplant system
go.drugbank.com/drugs/DB18692ExperimentalinBreath airway transplant system composes of a scaffold seeded with autologous bone marrow cells and incubated in the bioreactor for two days prior to implant.
Lunsekimig
go.drugbank.com/drugs/DB19009InvestigationalLunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).
Deudomperidone
go.drugbank.com/drugs/DB19055InvestigationalDeudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
p-Boronophenylalanine
go.drugbank.com/drugs/DB19158Investigationalp-Boronophenylalanine is under investigation in clinical trial NCT00039572 (Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain).
Peginterferon alfacon-1
go.drugbank.com/drugs/DB05860ExperimentalPEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalIt is important to take into consideration that normally, the cells in these hypoxic regions are resistant to radiotherapy and most anticancer drugs.
AX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased af...